Kairos Pharma (KAPA) Stock Price, News & Analysis

Company Overview

Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company focused on developing therapies for cancer. The company’s research centers on immuno-oncology, with an emphasis on addressing mechanisms that can cause tumors to resist existing treatments.

Kairos Pharma’s lead program, KPA-1102, is an investigational antibody designed to inhibit leukemia inhibitory factor (LIF), a signaling protein associated with tumor growth and immune suppression. The company is evaluating the potential use of this approach in combination with other cancer therapies, including immune checkpoint inhibitors.

The company is based in the United States and is focused primarily on advancing its drug candidates through clinical development and regulatory processes. As an emerging biotechnology company, Kairos Pharma’s operations and product portfolio remain centered on research, clinical trials and the development of its oncology pipeline.

Key Stats

• Today's Range: $1.72 to $1.78
• 50-Day Range: $1.58 to $2.73
• 52-Week Range: $1.51 to $9.59
• Volume: 42,261 shs
• Average Volume: 99,201 shs
• Market Capitalization: $5.83 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $63.00
• Consensus Rating: Buy

Kairos Pharma Stock Analysis - MarketRank™

Kairos Pharma scored higher than 62% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Kairos Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and no sell ratings.

Upside Potential

Kairos Pharma has a consensus price target of $63.00, representing about 3,562.8% upside from its current price of $1.72.

Amount of Analyst Coverage

Kairos Pharma has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Kairos Pharma are expected to decrease in the coming year, from ($2.59) to ($4.69) per share.

Price to Book Value per Share Ratio

Kairos Pharma has a P/B Ratio of 0.81. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.96% of the float of Kairos Pharma has been sold short.

Short Interest Ratio / Days to Cover

Kairos Pharma has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Kairos Pharma has recently decreased by 71.63%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Kairos Pharma does not currently pay a dividend.

Dividend Growth

Kairos Pharma does not have a long track record of dividend growth.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.50

News Sentiment

Kairos Pharma has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Kairos Pharma this week, compared to 1 article on an average week.

MarketBeat Follows

Only 1 people have added Kairos Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Kairos Pharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

31.90% of the stock of Kairos Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Kairos Pharma has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 9/25/2026
• Discovery on Target Conference: 9/30/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NYSEAMERICAN:KAPA
• CIK: 1962011
• Web: kairospharma.com
• Phone: (818) 404-5541
• Fax: N/A
• Employees: 1
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Kairos Pharma: $63.00
• High Price Target: $63.00
• Low Price Target: $63.00
• Potential Upside/Downside: +3,562.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$5.45 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -98.77%
• Return on Assets: -93.61%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 11.98
• Quick Ratio: 11.98

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.13 per share
• Price / Book: 0.81

Miscellaneous

• Outstanding Shares: 3,390,000
• Free Float: 2,306,000
• Market Cap: $5.83 million
• Optionable: N/A
• Beta: 1.48